Loading
Melbourne oncologist who led C-POST, the trial that showed cemiplimab after surgery and radiotherapy cuts recurrence in high-risk cutaneous squamous-cell carcinoma.
Danny Rischin directs medical oncology at the Peter MacCallum Cancer Centre and chairs head and neck trials for the Trans-Tasman Radiation Oncology Group. He was first author of the 2025 New England Journal of Medicine report of C-POST, in which adjuvant cemiplimab improved disease-free survival compared with placebo after surgery and radiotherapy for high-risk cutaneous squamous-cell carcinoma, and led the cemiplimab phase 2 programme in advanced disease.
| Title | Journal | Year |
|---|---|---|
| C-POST: adjuvant cemiplimab versus placebo in high-risk cutaneous squamous cell carcinoma | New England Journal of Medicine | 2025 |
Shares Advanced cutaneous squamous cell carcinoma, Skin cancer (all types), Head and neck squamous cell carcinoma and the tags skin, immunotherapy, trialist.
Shares Advanced cutaneous squamous cell carcinoma, Skin cancer (all types) and the tags skin, immunotherapy, trialist.
Shares Advanced cutaneous squamous cell carcinoma, Skin cancer (all types) and the tags skin, immunotherapy, trialist.
Shares Skin cancer (all types) and the tags skin, immunotherapy, trialist.
Shares Head and neck squamous cell carcinoma and the tags head-and-neck, immunotherapy, trialist.
Shares Advanced cutaneous squamous cell carcinoma, Skin cancer (all types) and the tags skin, immunotherapy.
Shares Head and neck squamous cell carcinoma and the tags head-and-neck, immunotherapy, trialist.
Shares Head and neck squamous cell carcinoma and the tags head-and-neck, immunotherapy.